Ioana Molnar

6PUBLICATIONS
21CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapySolid tumoursCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Dec 03, 2025
18F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2 + BC patients: a prospective and multicentric French study.

M Chanchou, M A Mouret-Reynier, I Molnar

|Mar 07, 2024
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.

Angeline Ginzac, Ioana Molnar, Xavier Durando

|Jul 03, 2023
Prediction of residual disease using circulating DNA detection after potentiated radiotherapy for locally advanced head and neck cancer (NeckTAR): a study protocol for a prospective, multicentre trial.

Angeline Ginzac, Marie-Céleste Ferreira, Anne Cayre

|Jul 29, 2021
Preoperative stereotactic radiosurgery for brain metastases: the STEP study protocol for a multicentre, prospective, phase-II trial.

Angeline Ginzac, Guillaume Dupic, Lucie Brun

|Jul 13, 2021
XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer.

Hugo Veyssière, Judith Passildas, Angeline Ginzac

|Oct 25, 2020
Analysis of 11 candidate genes in 849 adult patients with suspected hereditary cancer predisposition.

Mathias Cavaillé, Nancy Uhrhammer, Maud Privat

Pageof 1

Frequent Collaborators

4 joint publications

Xavier Durando

4 joint publications

Angeline Ginzac

2 joint publications

Julian Biau

2 joint publications

Véronique D'hondt